CYP2D6 testing for breast cancer patients: Is there more to the story?

ONCOLOGY

Volumn 23, Issue 14, 2009, Pages

  Henry, N Lynn ^a   Hayes, Daniel F ^a   Rae, James M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; AROMATASE INHIBITOR; CODEINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DRUG METABOLITE; ENDOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG; VENLAFAXINE;

BREAST CANCER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; NOTE; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 74249119050     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Note

References (13)

1. Kuderer NM, Peppercorn J: CYP2D6 testing in breast cancer: Ready for prime time? Oncology 23:1223-1232, 2009.
2. Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005.
3. Goetz MP, Knox SK, Suman VJ, et al: The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121, 2007.
4. Goetz MP, Rae JM, Suman VJ, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318, 2005.
5. Goetz MP, Suman V, Ames M, et al: Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: Long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial (abstract). Cancer Res 69(suppl):6037, 2009.
6. Lim HS, Ju Lee H, Seok Lee K, et al: Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845, 2007.
7. Schroth W, Antoniadou L, Fritz P, et al: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193, 2007.
8. Wegman P, Elingarami S, Carstensen J, et al: Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9:R7, 2007.
9. Wegman P, Vainikka L, Stal O, et al: Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284-290, 2005.
10. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003.
11. Borges S, Desta Z, Li L, et al: Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74, 2006.
12. Wijnen PA, Limantoro I, Drent M, et al: Depressive effect of an antidepressant: Therapeutic failure of venlafaxine in a case lacking CYP2D6 activity. Ann Clin Biochem 46:527-530, 2009.
13. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 101:1446-1452, 2009.